|
Market Closed -
Nasdaq
21:00:00 16/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.8600 USD | -4.09% |
|
-13.39% | -83.99% |
| 09-23 | Compass Therapeutics Shares Drop After Downgrade From Wedbush | MT |
| 09-23 | Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5 | MT |
Company Valuation: Compass Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 309 | 633.5 | 198.8 | 199.5 | 955.1 | 154.9 | - | - |
| Change | - | 105.02% | -68.61% | 0.34% | 378.75% | -83.78% | - | - |
| Enterprise Value (EV) 1 | 309 | 633.5 | 198.8 | 72.78 | 955.1 | 4.876 | 21.88 | 38.88 |
| Change | - | 105.02% | -68.61% | -63.39% | 1,212.3% | -99.49% | 348.67% | 77.71% |
| P/E | -2.42x | -13.6x | -4.73x | -4.03x | -12.8x | -1.73x | -1.54x | -1.95x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.4x | -0.44x | -0.8x | -0.1x | -0.1x | 0.1x |
| Capitalization / Revenue | - | - | - | 235x | - | - | 23.8x | 3.46x |
| EV / Revenue | - | - | - | 85.6x | - | - | 3.36x | 0.87x |
| EV / EBITDA | -3.8x | -15.5x | -4x | -1.3x | -13.2x | -0.05x | -0.2x | -0.31x |
| EV / EBIT | -3.77x | -15.2x | -3.95x | -1.29x | -13.1x | -0.05x | -0.19x | -0.38x |
| EV / FCF | -14.3x | - | - | -1.62x | -19.4x | -0.07x | -0.23x | -0.41x |
| FCF Yield | -6.98% | - | - | -61.7% | -5.15% | -1,492% | -437% | -244% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.31 | -0.37 | -0.33 | -0.36 | -0.42 | -0.496 | -0.5586 | -0.44 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 0.85 | - | - | 6.512 | 44.82 |
| EBITDA 1 | -81.32 | -40.87 | -49.66 | -56.04 | -72.56 | -99.95 | -111.9 | -124.7 |
| EBIT 1 | -81.88 | -41.66 | -50.36 | -56.62 | -72.84 | -98.56 | -113 | -102.6 |
| Net income 1 | -82.18 | -39.22 | -42.49 | -49.38 | -66.49 | -93.27 | -111.7 | -93.5 |
| Net Debt 1 | - | - | - | -126.7 | - | -150 | -133 | -116 |
| Reference price 2 | 3.1700 | 5.0300 | 1.5600 | 1.4500 | 5.3700 | 0.8600 | 0.8600 | 0.8600 |
| Nbr of stocks (in thousands) | 97,472 | 125,938 | 127,455 | 137,589 | 177,862 | 180,088 | - | - |
| Announcement Date | 18/03/22 | 15/03/23 | 21/03/24 | 27/02/25 | 05/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.73x | - | -0.05x | - | 155M | |
| 18.75x | 6.69x | 13.41x | 1.58% | 65B | |
| 27.56x | 7.53x | 23.83x | 0.05% | 51.19B | |
| 35.3x | 6.27x | 18.74x | 0.92% | 51.2B | |
| 34.01x | 3.32x | 14.33x | -.--% | 43.93B | |
| 48.9x | 5.59x | 30.73x | -.--% | 41.96B | |
| -18.47x | 189.62x | -19.51x | -.--% | 38.14B | |
| 28.97x | 8.21x | 21.25x | 0.37% | 33.24B | |
| 29.19x | 6.17x | 16.01x | -.--% | 25.2B | |
| -13.23x | 4.78x | -5.79x | -.--% | 22.03B | |
| Average | 18.92x | 26.46x | 11.29x | 0.32% | 37.21B | |
| Weighted average by Cap. | 23.34x | 24.98x | 14.00x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CMPX Stock
- Valuation Compass Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
